| Assessment Status | Rapid Review Complete |
| HTA ID | 20003 |
| Drug | Pegaspargase |
| Brand | Oncaspar® |
| Indication | As a component of antineoplastic combination therapy in acute lymphoblastic leukaemia in paediatric patients from birth to 18 years. |
| Assessment Process | |
| Rapid review commissioned | 05/02/2020 |
| Rapid review completed | 13/03/2020 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that pegaspargase (Oncaspar®) be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement, March 2020
